Japanese CRO EPS To Develop And Market Drugs In China
This article was originally published in PharmAsia News
Executive SummaryJapanese CRO EPS has entered the drug development business in China. The company has signed an agreement with Japanese mid-sized drug companies to market two drugs in China. Chinese clinical trials will be starting this year and the company aims for approvals by March 2010. EPS also plans to license five more drugs to market in China, and invest ¥100-¥200 million to start the clinical trials. EPS entered China in 1999, and the company has since established a Beijing EPS subsidiary to support new drug development. (Click here for more - Japanese language
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.